These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29475877)

  • 21. Adrenocortical carcinoma.
    Rodgers SE; Evans DB; Lee JE; Perrier ND
    Surg Oncol Clin N Am; 2006 Jul; 15(3):535-53. PubMed ID: 16882496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whole Body Metabolic Tumor Volume and Total Lesion Glycolysis Predict Survival in Patients with Adrenocortical Carcinoma.
    Satoh K; Patel D; Dieckmann W; Nilubol N; Kebebew E
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S714-20. PubMed ID: 26282908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors.
    Gara SK; Lack J; Zhang L; Harris E; Cam M; Kebebew E
    Nat Commun; 2018 Oct; 9(1):4172. PubMed ID: 30301885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry.
    Michalkiewicz E; Sandrini R; Figueiredo B; Miranda EC; Caran E; Oliveira-Filho AG; Marques R; Pianovski MA; Lacerda L; Cristofani LM; Jenkins J; Rodriguez-Galindo C; Ribeiro RC
    J Clin Oncol; 2004 Mar; 22(5):838-45. PubMed ID: 14990639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical management of adrenocortical carcinoma.
    Fassnacht M; Allolio B
    Best Pract Res Clin Endocrinol Metab; 2009 Apr; 23(2):273-89. PubMed ID: 19500769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment and management of advanced adrenocortical carcinoma using a precision oncology care model.
    Elfiky AA; Krishnan Nair HK
    Discov Med; 2016 Jan; 21(113):49-56. PubMed ID: 26896602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adrenocortical carcinomas: a 12-year clinicopathologic study of 15 cases.
    Menon V; Krishnamurthy SV
    Indian J Pathol Microbiol; 2006 Jan; 49(1):7-11. PubMed ID: 16625963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathological and Genetic Stratification for Management of Adrenocortical Carcinoma.
    Clay MR; Pinto EM; Fishbein L; Else T; Kiseljak-Vassiliades K
    J Clin Endocrinol Metab; 2022 Mar; 107(4):1159-1169. PubMed ID: 34850906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2D-DIGE proteomic analysis identifies new potential therapeutic targets for adrenocortical carcinoma.
    Poli G; Ceni E; Armignacco R; Ercolino T; Canu L; Baroni G; Nesi G; Galli A; Mannelli M; Luconi M
    Oncotarget; 2015 Mar; 6(8):5695-706. PubMed ID: 25691058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgical management of adrenocortical carcinoma.
    Ranvier GG; Inabnet WB
    Endocrinol Metab Clin North Am; 2015 Jun; 44(2):435-52. PubMed ID: 26038210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histologic criteria for adrenocortical proliferative lesions: value of mitotic figure variability.
    Blanes A; Diaz-Cano SJ
    Am J Clin Pathol; 2007 Mar; 127(3):398-408. PubMed ID: 17276949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literature.
    Wanis KN; Kanthan R
    World J Surg Oncol; 2015 Mar; 13():117. PubMed ID: 25889798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnosis, treatment and outcome of adrenocortical cancer.
    Mihai R
    Br J Surg; 2015 Mar; 102(4):291-306. PubMed ID: 25689291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current and emerging therapies for adrenocortical carcinoma--review.
    Przytulska J; Rogala N; Bednarek-Tupikowska G
    Adv Clin Exp Med; 2015; 24(2):185-93. PubMed ID: 25931348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification.
    Fassnacht M; Johanssen S; Quinkler M; Bucsky P; Willenberg HS; Beuschlein F; Terzolo M; Mueller HH; Hahner S; Allolio B; ;
    Cancer; 2009 Jan; 115(2):243-50. PubMed ID: 19025987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors.
    Fonseca AL; Kugelberg J; Starker LF; Scholl U; Choi M; Hellman P; Åkerström G; Westin G; Lifton RP; Björklund P; Carling T
    Genes Chromosomes Cancer; 2012 Oct; 51(10):949-60. PubMed ID: 22733721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adrenocortical carcinoma: review and update.
    Erickson LA; Rivera M; Zhang J
    Adv Anat Pathol; 2014 May; 21(3):151-9. PubMed ID: 24713984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples.
    Gara SK; Wang Y; Patel D; Liu-Chittenden Y; Jain M; Boufraqech M; Zhang L; Meltzer PS; Kebebew E
    Nucleic Acids Res; 2015 Oct; 43(19):9327-39. PubMed ID: 26446994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
    Ragazzon B; Libé R; Gaujoux S; Assié G; Fratticci A; Launay P; Clauser E; Bertagna X; Tissier F; de Reyniès A; Bertherat J
    Cancer Res; 2010 Nov; 70(21):8276-81. PubMed ID: 20959480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
    Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
    Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.